MarketBeat54d agoneutral
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline AdvancesNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
104last 24h
3124last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
MarketBeat60d agoneutral
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution ModePharmaceutical Technology60d agoneutral
Gilead launches research facility in US for new medicine developmentInsider Monkey62d agoneutral
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?Simply Wall St.65d agoneutral
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?24/7 Wall St.65d agoneutral
Gilead Keeps Writing Bigger Checks - But Can the Drugs Keep Paying for Them?Simply Wall St.73d agobullish
Gilead Sciences (GILD) Wins EU Trodelvy Approval, Is The Stock Fully Priced?Simply Wall St.73d agoneutral
What Does Gilead Sciences (GILD) Gain From Its Expanded EU Breast Cancer Approval?